顺铂作为卵巢癌的一线治疗方案，与肾毒性和造血毒性等严重副作用有关。本研究旨在确定纳米姜黄素联合顺铂治疗是否能为卵巢癌大鼠肾功能和血液参数带来额外的益处。将25只Wistar大鼠分为5只未治疗大鼠和20只二甲基苯并(a)蒽（DMBA）诱导的卵巢癌大鼠。20只卵巢癌大鼠分为4组治疗：空白对照组、顺铂组、顺铂-姜黄素组和顺铂-纳米姜黄素组。顺铂给予4 mg/kg体重，每周一次，姜黄素或纳米姜黄素每日100mg/kg体重，治疗4周。治疗结束后，我们从血浆中分析肾功能、血液学参数以及炎症和氧化应激标志物。纳米姜黄素缓解了顺铂治疗的大鼠肾功能标志物增加和血液学指标异常的情况。相比于接受顺铂治疗的大鼠，血浆尿素水平从66.4 mg/dL下降到47.7 mg/dL，肌酐水平从0.87 mg/dL降到0.82 mg/dL，中性粒细胞凝胶酶相关脂蛋白（NGAL）水平下降从8.51 mIU/mg蛋白质到3.59 mIU/mg蛋白质。此外，治疗还增加了谷胱甘肽活性（从2.02 U/µL到3.23 U/µL），减少了脂质过氧化（从0.54 nmol/mL到0.45 nmol/mL），并减少了血浆TNF-α水平（从270.6 pg/mL到217.8 pg/mL）。顺铂与纳米姜黄素在卵巢癌大鼠模型中的联用可能作为一种预防药物，对抗肾功能损害和顺铂引起的造血毒性。然而，需要进一步研究证明纳米姜黄素的抗癌属性不受影响。

Cisplatin, as a first-line treatment for ovarian cancer, is associated with debilitating adverse effects, including nephrotoxic and haematotoxic effects.This study determines whether nanocurcumin, combined with cisplatin, would give additional benefit to kidney function and haematological parameters in rats with ovarian cancer.Twenty-five Wistar rats were divided into five untreated rats and 20-dimethylbenz(a)anthracene (DMBA)-induced ovarian cancer rats. The 20 ovarian cancer rats were divided into four treatment groups: vehicle, cisplatin, cisplatin-curcumin, and cisplatin-nanocurcumin. Cisplatin was given at the dose of 4 mg/kg BW once weekly, while curcumin or nanocurcumin was administered at 100 mg/kg BW daily for four weeks. At the end of treatment, we analysed kidney function, haematological parameters, and inflammatory and oxidative stress markers from plasma.Nanocurcumin alleviates the increase in kidney function markers and abnormalities in haematological indices in rats treated with cisplatin. Compared to cisplatin-treated rats, plasma urea levels decreased from 66.4 to 47.7 mg/dL, creatinine levels lowered from 0.87 to 0.82 mg/dL, and neutrophil gelatinase-associated lipocalin (NGAL) levels declined from 8.51 to 3.59 mIU/mg protein. Furthermore, the therapy increased glutathione activities (from 2.02 to 3.23 U/µL), reduced lipid peroxidation (from 0.54 to 0.45 nmol/mL), and decreased plasma TNF-α (from 270.6 to 217.8 pg/mL).Cisplatin with nanocurcumin in an ovarian cancer rat model may provide additional benefits as a preventive agent against renal impairment and cisplatin-induced haematological toxicity. However, further research is required to prove that using nanocurcumin for a more extended time would not affect its anticancer properties.